Follow
Gabriel Gallo-Oller
Gabriel Gallo-Oller
DISIT Biotech
Verified email at disitbiotech.com
Title
Cited by
Cited by
Year
A new background subtraction method for Western blot densitometry band quantification through image analysis software
G Gallo-Oller, R Ordonez, J Dotor
Journal of immunological methods 457, 1-5, 2018
1822018
Inhibitors of ribosome biogenesis repress the growth of MYCN-amplified neuroblastoma
ØH Hald, L Olsen, G Gallo-Oller, LHM Elfman, C Løkke, P Kogner, ...
Oncogene 38 (15), 2800-2813, 2019
642019
miRNA-7 and miRNA-324-5p regulate alpha9-Integrin expression and exert anti-oncogenic effects in rhabdomyosarcoma
C Molist, N Navarro, I Giralt, P Zarzosa, G Gallo-Oller, G Pons, ...
Cancer Letters 477, 49-59, 2020
302020
Establishment and characterization of an orthotopic patient-derived Group 3 medulloblastoma model for preclinical drug evaluation
E Sandén, C Dyberg, C Krona, G Gallo-Oller, TK Olsen, J Enríquez Pérez, ...
Scientific Reports 7 (1), 46366, 2017
292017
P144, a Transforming Growth Factor beta inhibitor peptide, generates antitumoral effects and modifies SMAD7 and SKI levels in human glioblastoma cell lines
G Gallo-Oller, A Vollmann-Zwerenz, B Meléndez, JA Rey, P Hau, J Dotor, ...
Cancer letters 381 (1), 67-75, 2016
292016
Dickkopf proteins and their role in cancer: a family of Wnt antagonists with a dual role
I Giralt, G Gallo-Oller, N Navarro, P Zarzosa, G Pons, A Magdaleno, ...
Pharmaceuticals 14 (8), 810, 2021
212021
RITA downregulates Hedgehog-GLI in medulloblastoma and rhabdomyosarcoma via JNK-dependent but p53-independent mechanism
A Azatyan, G Gallo-Oller, Y Diao, G Selivanova, JI Johnsen, ...
Cancer letters 442, 341-350, 2019
162019
Transforming growth factor beta (TGF-β) activity in immuno-oncology studies
G Gallo-Oller, M Di Scala, F Aranda, J Dotor
Methods in Enzymology 636, 129-172, 2020
112020
Quantitative method for in vitro matrigel invasiveness measurement through image analysis software
G Gallo-Oller, JA Rey, J Dotor, JS Castresana
Molecular biology reports 41, 6335-6341, 2014
102014
Integrin alpha9 emerges as a key therapeutic target to reduce metastasis in rhabdomyosarcoma and neuroblastoma
N Navarro, C Molist, J Sansa-Girona, P Zarzosa, G Gallo-Oller, G Pons, ...
Cellular and Molecular Life Sciences 79 (11), 546, 2022
92022
Dickkopf-1 inhibition reactivates Wnt/β-catenin signaling in rhabdomyosarcoma, induces myogenic markers in vitro and impairs tumor cell survival in vivo
I Giralt, G Gallo-Oller, N Navarro, P Zarzosa, G Pons, A Magdaleno, ...
International Journal of Molecular Sciences 22 (23), 12921, 2021
92021
PPM1D Is a Therapeutic Target in Childhood Neural Tumors
J Milosevic, D Treis, S Fransson, G Gallo-Oller, B Sveinbjörnsson, ...
Cancers 13 (23), 6042, 2021
82021
Genome-wide microarray expression and genomic alterations by array-CGH analysis in neuroblastoma stem-like cells
R Ordóñez, G Gallo-Oller, S Martínez-Soto, S Legarra, N Pata-Merci, ...
PloS one 9 (11), e113105, 2014
82014
High Expression of PPM1D Induces Tumors Phenotypically Similar to TP53 Loss-of-Function Mutations in Mice
J Milosevic, S Fransson, M Gulyas, TK Olsen, G Gallo-Oller, D Treis, ...
Cancers 13 (21), 5493, 2021
72021
Sonic hedgehog inhibition reduces in vitro tumorigenesis and alters expression of Gli1-target genes in a desmoplastic medulloblastoma cell line
R García-López, B Vera-Cano, A Vacas, FJ Rosa-Fernández-Pacheco, ...
72013
Targeting the hedgehog pathway in rhabdomyosarcoma
P Zarzosa, L Garcia-Gilabert, R Hladun, G Guillén, G Gallo-Oller, G Pons, ...
Cancers 15 (3), 727, 2023
62023
In vitro tumorigenicity and stemness characterization of the U87MG glioblastoma cell line based on the CD133 cancer stem cell marker
A Vacas-Oleas, J de la Rosa, R García-López, B Vera-Cano, ...
Open Access Sci Rep 2, 609, 2013
52013
TRIB3 silencing promotes the downregulation of Akt pathway and PAX3-FOXO1 in high-risk rhabdomyosarcoma
G Gallo-Oller, G Pons, J Sansa-Girona, N Navarro, P Zarzosa, ...
Experimental Hematology & Oncology 13 (1), 38, 2024
32024
Analysis of cancer genomic amplifications identifies druggable collateral dependencies within the amplicon
G Pons, G Gallo-Oller, N Navarro, P Zarzosa, J Sansa-Girona, ...
Cancers 15 (6), 1636, 2023
22023
Combined inhibition of MDM2 and PARP lead to a synergistic anti-tumoral response in p53 wild-type rhabdomyosarcoma
G Pons, G Gallo-Oller, L García-Gilabert, P Zarzosa, J Sansa-Girona, ...
Cancer Research 84 (6_Supplement), 5473-5473, 2024
12024
The system can't perform the operation now. Try again later.
Articles 1–20